These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimen.
    Author: Marcelin AG, Jarrousse B, Derache A, Ba M, Dakouo ML, Doumbia A, Haidara I, Maïga A, Carcelain G, Peytavin G, Katlama C, Calvez V.
    Journal: AIDS; 2007 Nov 12; 21(17):2341-3. PubMed ID: 18090283.
    Abstract:
    Early failures to stavudine/lamivudine/nevirapine used as a generic fixed-dose combination in Mali showed resistance mutations in 50% of cases (mostly M184V and Y181C). No thymidine analogue mutations were seen, suggesting that most nucleoside reverse transcriptase inhibitors could be used in a second-line regimen. This highlights the importance of the accessibility of HIV-RNA assays for monitoring treated patients in resource-poor countries to detect early virological failure in order to preserve future therapeutic options.
    [Abstract] [Full Text] [Related] [New Search]